Amarantus Bioscience Fakten-Thread - 500 Beiträge pro Seite

[franzisca]

Bitte hier nur reine Fakten posten!

Liebe Grüsse franzisca





http://www.wallstreet-online.de/diskussion/1177630-1-10/amar…

http://www.amarantus.com/

http://investorshub.advfn.com/boards/board.aspx?board_id=217…

http://finance.yahoo.com/mb/AMBS/

http://otcshortreport.com/AMBS

[haseausdemhut]

hier der realtimechart, die charts hier sind etwas launisch,

falls nicht zu sehen, auf das "bild" mit dee maus rechts klicken und tab im neuen fenster öffnen, dann gehts auf jeden fall.





oder auf diesen link klicken, realtimechart:

http://ih.advfn.com/p.php?pid=staticchart&s=ambs&p=0&t=19&vo…

[haseausdemhut]

zuerst nur eine news aus 2011, die nächsten sind ab 2012.
AUGUST 2011

Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes

Amarantus Bioscience, Inc. Common stock (OTCBB:AMBS)



SUNNYVALE, Calif. and TORONTO, Aug. 4, 2011 /PRNewswire/ -- Amarantus BioSciences (OTCBB: AMBS), a biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com), a biotechnology company developing a buccal insulin spray technology known as Generex Oral-lyn™, currently in a Phase III trial, today are making public the details of their intended third joint diabetes research collaboration. In this third research project, the companies will use Amarantus' proprietary PhenoGuard cell immortalization process to develop beta cell replacement therapies to aid diabetes therapy. The two companies are currently planning to develop a MANF-based diagnostic test to identify a sub-population at risk of developing Type 1 or Type 2 diabetes as well as a MANF-based therapeutic to be administered using the RapidMist™ delivery system for the treatment of diabetes and impaired glucose tolerance.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

"The potential of Amarantus' proprietary PhenoGuard cell immortalization process to create a stable source of representative beta cells that can be used in cell replacement therapy in patients who have lost virtually all beta cell function represents a potential major breakthrough for the treatment of chronic, late-stage diabetes," said Dr. James Anderson, Senior Scientific Advisor and Director of Generex. "Patients whose beta cell function is most impaired are the ones most at-risk of developing life-threatening complications of diabetes. Beta cell replacement therapy taken together with the development of a diagnostic test able to track the progression of beta cell dysfunction, and the ability to administer MANF prophylactically and therapeutically to alter the course of beta cell apoptosis and dysfunction in patients with diabetes and pre-diabetes disorders, these three research collaboration programs represent major research and development initiatives that could dramatically alter the course of treatment in the diabetes space. The breadth and scope of this research collaboration provides Generex with an incredible opportunity to position itself as a long-term market leader in the treatment of diabetes-related metabolic disorders."

"To date, the Amarantus PhenoGuard technologies have been able to immortalize cells in a manner that maintains the phenotypic characteristics of the cells being immortalized," said Dr. John Commissiong, Chief Scientific Officer of Amarantus. "The potential to create immortal clones of beta cells that could be used in cell therapy procedures would further validate the Amarantus technologies, positioning Amarantus as a unique resource for novel cell lines, while creating a powerful tool to change the clinical outcomes in patients with the most severe forms of diabetes."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases. The Company's most advanced product candidate, MANF, is a therapeutic protein indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute in Sunnyvale, CA, Amarantus BioSciences is the recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research. See www.Amarantus.com.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

[haseausdemhut]

11.januar 2012

Amarantus BioSciences Awarded US Patent Protecting Composition of Matter for MANF

-------------------------------------------------------

23.januar 2012

Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products

--------------------------------------------------------

7.juni 2012

Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration

-------------------------------------------------------

25. september 2012

Amarantus BioSciences Co-Founders honored among 2012's "50 Most Important African-Americans in Technology"

------------------------------------------------------

11.oktober 2012

Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test

------------------------------------------------------

17.oktober 2012

Amarantus Biosciences Awarded Research Grant by Center of Excellence in Apoptosis Research

----------------------------------------------------------
25.oktober 2012


Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parki...

------------------------------------------------------

Quelle:

http://ih.advfn.com/p.php?pid=news&btn=&ctl00%24sb3%24tbq1=G…

[haseausdemhut]

6.11.2012

http://www.kxxv.com/story/20013386/amarantus-biosciences-app…


Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board


Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Amarantus BioSciences, Inc.

SUNNYVALE, Calif., Nov. 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.

"Clearly, Dr. Rubinfeld joining the Advisory Board is a tremendous endorsement for the Company at this critical juncture in our growth cycle," said Gerald E. Commissiong, President & CEO of Amarantus. "The Advisory Board is now well populated with extremely talented experts in the various fields that are necessary to position us for growth: science, investment banking/M&A, business development and regulatory affairs. We now intend to leverage these relationships to fill out the management team and Board of Directors with development expertise and Big Pharma experience in order to attract the capital necessary to advance our development programs towards key value inflexion milestones."

Dr. Rubinfeld is the fourth member of Amarantus' Advisory Board. The bios of the other members of the Company's Advisory Board are below:

Owen Garrick, MD MBA

Dr. Owen Garrick currently serves as the President & Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.

Mark Benedyk, PhD

Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Dr. Benedyk is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University's Graduate School of Business, and the University of Virginia Darden School of Business.

Clinton Allen, MSc

Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
[e-mail]

©2012 PR Newswire. All Rights Reserved

[haseausdemhut]

OKTOBER/NOVEMBER 2012

1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.

2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.

3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.

4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.

5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."

Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.

6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!

------------------------------------------------------


1. AMBS acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC

2. AMBS had Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;

3. AMBS Secured the license for the NuroPro Parkinson's diagnostic blood test;

4. AMBS Successfully concluded its research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.

5. AMBS anticipates announcing interim results from on-going delivery experiments by the end of October.

6. AMBS has a Parkinson’s disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinson’s—a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s research...

7. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinson’s that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients. The Companies believe that Amarantus’ NuroPro test for Parkinson’s disease could be on market in certain regions as early as 2013.

8. Over $30MM has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.

9. According to a2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75BB by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson’s drug market. There are currently no diagnostic tests available for Parkinson’s disease, thus making AMBS test a first of its kind product capable of gaining a market leading position.

10. AMBS announced Drug Test Results & the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls

[haseausdemhut]

the buyalert from equities.com

November 15th, 2012: The most ACTIVE Analytical Penny Stocks (OTCQB: AMBS)
Oje Icahn Partners, Inc MacReport Media

ThePennyStockTapeReader.com is going to cover the following stocks in the next 24 hours and give you a an honest view of where the trading of these stocks are moving toward based on the criteria we use to read the tape, you want to join us, as you will learn how to trade these stocks and also future trade opportunities.
Amarantus Biosciences, Inc. (OTCQB: AMBS)
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company focuses on developing its intellectual property and proprietary technology to develop drug candidates to treat human disease. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). The company announced today that it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.

http://www.equities.com/news/headline-story?dt=2012-11-15&va…

[haseausdemhut]

Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding


SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company ............. today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.

..........the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's ...................... Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."

The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.[1]

A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.

zum vollständigen text: http://ih.advfn.com/p.php?pid=nmona&article=54787798

[haseausdemhut]

ALS DIESE NACHRICHT ERSCHIEN WAR DER KURS BEI CA 0,04 uscent:


Amarantus BioSciences Secures $1.1 Million in Financing


SUNNYVALE, Calif., Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), reconcile certain of Amarantus' outstanding payables, and for general working capital.

Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000. The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share, subject to certain provisions. The note is not convertible into common shares for 6 months, and the Company has the option to pay the note in cash at its discretion at any time. Monies will be paid to Amarantus under the note in four separate tranches of $150,000 over a 6 week period, subject to certain milestones. The Investor agreed to "no shorting" provisions.

Amarantus entered into an unrelated equity financing arrangement with a separate long-only institutional fund (the "Fund") that assists public companies in financing operations and expansion. The Company settled over $500,000 in accounts payable, which the fund had acquired from various creditors of the Company, in exchange for shares of common stock. The transaction substantially reduced the Company's liabilities, including a portion of its outstanding accounts payable balance. The Fund agreed to "no shorting" provisions.


http://ih.advfn.com/p.php?pid=nmona&article=55025946

[haseausdemhut]

RBCC: Short R&D Timeline Could Lead to Larger Profits

NOKOMIS, Fla., Nov 19, 2012 (BUSINESS WIRE) -- As Rainbow Coral Corp. looks ahead to a successful 2013, the company has placed a high priority on initiating projects that will realize profits quickly.



The first project to be fast-tracked will be the company's joint venture with Amarantus BioSciences (OTCBB: AMBS). Both companies forswear realizing revenues from the impending commercialization of Amarantus' NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson's disease. NuroPro works by identifying differentiated levels proteins and peptides in the blood of patients who have the disease.


RBCC and Amarantus expect to finalize NuroPro's development timeline within the next 12-14 months. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal.

The shortened timeline became a possibility last week when Amarantus secured over $1.1 million in funding through two separate transactions. RBCC plans to invest in the ongoing development of NuroPro and to be repaid for its investment out of proceeds from the sales generated by the revolutionary diagnostic blood test.

If milestones are met, RBCC will then share in its revenues sooner than originally anticipated, once the initial investment is repaid.

For more information on Rainbow BioSciences' neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

[haseausdemhut]

wie die börse funktioniert....

[haseausdemhut]

email vom ambs ceo:


From:Gerald Commissiong <[e-mail]>

To:
Cc:
Date: Thursday, November 22, 2012 04:15 pm
Subject: Re: Happy Thanksgiving

Hello ***,

Thanks for the wishes and Happy Thanksgiving to you to. Day to day trading goes up and down. Just like you I prefer to see it go up, but this is the nature of the beast. The most important thing I can do is continue to build the business and keep shareholders as up to date as possible on developments inside the Company. We are building this for the long-run.

Best Regards,

Gerald

Gerald Commissiong
President & CEO
Amarantus BioSciences, Inc.
C/O The Parkinson's Institute
675 Almanor Ave.
Sunnyvale, CA 94085
[e-mail]

www.amarantus.com
Ph: 408-737-2734
Fax: [phone]

[haseausdemhut]

23.november 2012

OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Effica...


ONEMEDPLACE: These data serve as strong evidence that positions MANF as a potential breakthrough therapeutic treatment for ischemic heart conditions. This study adds to an accumulating body of research that all corroborate the therapeutic effects of MANF. Since its original discovery in 2003, MANF has been the subject of over 20 independent studies that identify its ability to treat disease states.

....Taken together these studies delineate the vast potential of MANF as a therapeutic, providing Amarantus with the requisite empirical evidence needed to propel this drug candidate into advanced developmental stages and clinical trials."

http://ih.advfn.com/p.php?pid=nmona&article=55159199


http://www.onemedplace.com/reports/Amarantus_Research_Update…

[haseausdemhut]

HISTORY AMBS (very short)

NOVEMBER 2012

*ONEMEDPLACE REPORT: These data serve as strong evidence that positions MANF as a potential breakthrough therapeutic treatment for ischemic heart conditions. This study adds to an accumulating body of research that all corroborate the therapeutic effects of MANF. Since its original discovery in 2003, MANF has been the subject of over 20 independent studies that identify its ability to treat disease states.

....Taken together these studies delineate the vast potential of MANF as a therapeutic, providing Amarantus with the requisite empirical evidence needed to propel this drug candidate into advanced developmental stages and clinical trials."

*Amarantus BioSciences Wins MANF Patent Challenge in Europe:

*Amarantus BioSciences to Present at CNS Summit 2012

*Amarantus BioSciences Secures $1.1 Million in Financing, convertibles for 0,10$

*Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinson's Blood Test Joint Venture

*Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding

*Amarantus BioSciences Appoints Dr. Robert J. Zimmerman (BAYER biotech director) as Product Development Advisor

*Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board

OKTOBER

*Amarantus BioSciences Appoints Clinton O. Allen (Bristol Myers Squibb Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development) To Advisory Board

*Amarantus Biosciences Awarded Research Grant by Center of Excellence in Apoptosis Research

*Amarantus BioSciences Acquires Option to License LymPro Alzheimer's Diagnostic Blood Test

SEPTEMBER

*Amarantus BioSciences Co-Founders honored among 2012's "50 Most Important African-Americans in Technology"

JUNE

*Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine

*Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA)122nd Conference in New York City

MAY

*Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012

MARCH

*Amarantus BioSciences Reports Addition of New Scientific Articles to MANF Publications List

FEBRUAR

*AMBS present preclinical data on MANF at the 14th Annual Meeting of the American Society of Experimental Neurotherapeutics (ASENT) Conference at the Ritz Carlton Hotel in Washington, D.C.

NOVEMBER 2011

*GLOBE: Amarantus Biosciences, a Promising Biotech Company in Development.

OKTOBER

*Amarantus BioSciences Receives Notice of Allowance for U.S. Patent Covering MANF Discovery

JULY

*Amarantus BioSciences and Generex Biotechnology Announce Collaboration to Treat Pre-Diabetes

JUNE

*Generex Biotechnology and Amarantus BioSciences Announce Oral-lyn-Focused Collaboration Program

----------------------------------------------------------------------------

[haseausdemhut]

224 million O/S sind outstanding shares, also aktien die herausgegeben worden sind,
es ist die gesamtanzahl von aktien die im markt, bei investoren und insidern gehalten werden.
von die 224 millionen aktien sind 149 millionen im float (im markt für uns erhältlich) 75 millionen in investoren händen. und 10% wird von insidern gehalten.

[haseausdemhut]

http://www.pharmiweb.com/pressreleases/


Nov.26.2012
Rainbow Coral Corp. (OTCBB: RBCC) joint venture target Amarantus BioSciences (OTCBB: AMBS) recently announced the company will seek orphan drug designation from the FDA for MANF, the therapeutic protein developed to treat Parkinson’s disease and traumatic brain injuries.

The Orphan Drug Act, passed by Congress in 1983, provides for the granting of special status to a product used to treat rare diseases. Orphan drug designation means that the drug sponsor qualifies for certain benefits, such as reduced taxes, from the federal government.

While Parkinson’s disease and traumatic brain injury are both afflictions suffered by large populations of patients worldwide, Amarantus’ research indicates that MANF may also be well-suited to treating many rare and ultra-rare neurological ailments, as well. By pursuing orphan drug status, the joint venture could potentially fast-track MANF on an accelerated timetable requiring fewer and smaller clinical trials for commercialization.

Competitors such as Genzyme, FerroKin Biosciences and Alexion Pharmaceuticals have leveraged orphan drugs into buyouts totaling billions of dollars in recent years, raising Amarantus’ expectations for MANF.

Amarantus recently received millions in new funding to continue their research and development work. The joint venture’s first priority will be the speedy commercialization of Amarantus’ NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinson’s disease.

For more information on Rainbow BioSciences’ neurological treatment initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories (NYSE: ABT).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.


Business Wire
http://www.businesswire.com/

Last updated on: 26/11/2012 16:00:08


http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=67439#axzz2DLch2KKG

[haseausdemhut]

PROACTIVE INVESTORS USA & CANADA:

http://www.proactiveinvestors.com

RELEASE: AMARANTUS BIOSCIENCES ANNOUNCES POSITIVE DATA FOR MANF IN DELIVERY DIFFUSION ANIMAL MODEL OF PARKINSON’S DISEASE
Wed 2:53 pm by OneMedPlace Team
**The following is a press release from Amarantus BioSciences highlighting promising data in Parkinson’s Disease for its anti-apoptosis therapeutic protein MANF.**

http://www.proactiveinvestors.com/columns/one-med-place/2699/release-amarantus-biosciences-announces-positive-data-for-manf-in-delivery-diffusion-animal-model-of-parkinsons-disease-2699.html

[haseausdemhut]

Amarantus Bioscience Announces Publication of Peer-Reviewed Data for MANF in Ischemia-Induced Neural Injury

SUNNYVALE, Calif., Nov. 29, 2012 /PRNewswire via COMTEX/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that an independent peer-reviewed research paper entitled Upregulation of mesencephalic astrocyte-derived neurotrophic factor in glial cells is associated with ischemia-induced glial activation was published in the Journal of Neuroinflammation. The research paper concludes: "These results indicate that MANF expression was up-regulated in the activated glial cells, which may contribute to the mechanism of ischemia-induced neural injury." Glial cells are non-neuronal cells that maintain homeostasis, form myelin, and provide support and protection for neurons in the brain, and for neurons in other parts of the nervous system.
In this research paper, the authors describe the process by which MANF is upregulated in glial cells in response to induced cerebral ischemia. The authors identified that while MANF was consistently expressed in neurons in both the normal and ischemic cerebral cortex, MANF expression in astrocytes was down-regulated under normal conditions, whereas MANF expression in astrocytes was heavily upregulated under ischemic conditions in the cortex. This result provides further evidence to support the theory that MANF is upregulated by cells in times of stress in order to maintain cell viability.

MANF was discovered from the first of Amarantus' 88 proprietary PhenoGuard astrocyte cell lines. Astrocytes are glial cells in the brain that support neuroprotection, neurogenesis and synaptogenesis. PhenoGuard is the cell immortalization process developed by Company scientists to create immortal lines of astrocytes from various parts of the brain associated with neurodegenerative diseases. These immortal lines give the Company a competitive advantage in the search for undiscovered neurotrophic factors that address critically important biological pathways involved in human diseases. The Company believes it can discover a stable of novel MANF-like proteins using its proprietary PhenoGuard platform technology. PhenoGuard was originally developed in the Neurotrophic Factors Group at the National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

[haseausdemhut]

"SUNNYVALE, Calif., Dec. 3, 2012

The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals."



http://ih.advfn.com/p.php?pid=nmona&article=55291531

[haseausdemhut]

4.12.2012

http://seekingalpha.com/article/1042461-acadia-hits-home-run…

About AMBS:

Quote:
Amarantus Bioscience (AMBS.OB)is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.


Quote:
The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, the company announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug.


About Parkinson's disease:

Quote:
Parkinson's disease psychosis is a debilitating disorder that develops in up to 60% of patients with Parkinson's disease. Currently, there is no FDA-approved therapy to treat PDP in the United States.

[haseausdemhut]

http://m.prnewswire.com/news-releases/amarantus-appoints-sup…

[haseausdemhut]

6.dez,2012

224 millionen aktien O/S x aktueller pps = marketcap.

von 224 millionen sind ca 149 millionen (ca 66%) im float (im markt für uns erhältlich),
und ca 75 millionen (34%)sind in institionelle investorenhänden.

von den 149 millionen sind sind bestimmt gut die hälfte in festen händen (fonds, private investoren, ich)

an die runde:

damit wir dimension verstehen:

Lympro ich glaube kurz vor zulassung (einzigartig imm markt),
Nuropro phase II nicht weit von der zulassung evntl Orphan drug status(einzigartig im markt),
MANFpreklinik höchstwahrscheinlich bald in trial phase.

es ist ein multimilliardenmarkt.

unterbewertet ist noch untertrieben, vergleichbare firmen haben eine marketkapitalisierung von 75-100 millionen $ im jetzigen stadium. es kommt auf deine anlagehorizont an.es passiert alle schaltjahre mal das wir so eine gelegenheit bekommen, stell dir vor in den nächsten monaten erhält ambs die fda zulassung (Nuropro und Lympro),
der wert der aktie wäre bei 2$-4$.
und der größte hoffnungsträger MANF bei zulassung egal ODA/FDA...ich weiss es nicht, es sprengt sogar meine vorstellungskraft,10$-20$..50$, es ist auf jedenfall wie gesagt ein multimilliardenmarkt.

als hausaufgabe für jeden schaut euch diesen chart von Amgen dessen mitbegründer jetzt bei uns mit am bord ist, er hat aus seiner firma auch aus 0,02cent großgezogen zur 90$ pro aktie (marketcap ich glaub ca 60Milliarden):

wenn nicht schon bei maximale zeit anzeigt klickt über dem chart bei zoom auf "all", und logarhytmisch ansehen natürlich.

http://www.google.com/finance?q=NASDAQ:AMGN&ei=_8K8UNi7KOGEw…

[haseausdemhut]

News 06.12.2012

$AMBS >>news !>> Amarantus Bioscience to Present at OneMedForum 2013 SUNNYVALE, Calif., Dec. 6, 2012 /PRNewswire via COMTEX/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it will be presenting at the OneMedForum 2013 healthcare conference on Tuesday, January 8th, 2013 at 2pm Pacific. OneMedForum 2013 will be held at the Sir Francis Drake Hotel during the week of the J.P. Morgan 31st Annual Healthcare Conference in San Francisco. A link to the live webcast of the presentation will be made available to the public prior to the conference.About OneMedForumEstablished in 2008, OneMedForum is the conference component of OneMedPlace, which provides an integrated media platform to showcase the best ideas and innovations in health and medicine globally. The media platform also includes: OneMedRadio; OneMedTV, OneMedSentinel; a global database of companies; and OneMedResearch, which tracks promising lesser-known microcap public companies. For more information visit the conference website. www.onemedforum.com

[haseausdemhut]

Exciting Field In Cure For Parkinson's

Dec 7, 2012 8:20 AM | about stocks: AMBS.OB, AMGN, BMY
I recently wrote an article covering some companies attempting tofind a cure for Parkinsons. As a follow up, I wanted to write about an exciting field of neutrophic factors that are being used in an attempt to treat Parkinsons.

Neutrophic factors are a family of proteins that are responsible for the growth and survival of developing neurons and the maintenance of mature neurons. Recent research has proven that neurotrophic factors promote the initial growth and development of neurons in the central nervous system and peripheral nervous system and that they are capable of restoring damaged neurons in test tubes and animal models. Neurotrophic factors are often released by the target tissue in order to guide the growth of developing axons. Currently, neurotrophic factors are being intensely studied for use in bioartificial nerve conduits because they are necessary in vivo for directing axon growth and regeneration. In studies, neurotrophic factors are normally used in conjunction with other techniques such as biological and physical cues created by the addition of cells and specific topographies.

In this article I'm going to cover 3 different neutrophic factors, glial cell-derived neurotrophic factor or GDNF, cerebral dopamine neurotrophic factor or CDNF, and mesencephalic astrocyte-derived neurotrophic factor or MANF as part of a two part series. Providing assistance in this article is Henri Huttunen, Ph.D., CSO and Partner from Hermo Pharma Oy Ltd., a privately owned, venture capital backed company based in Finland working on therapeutic approaches for currently untreatable medical needs, particularly Parkinson's disease. Hermo Pharma is a recent recipient of approximately $700,000 in grants from the Michael J. Fox Foundation.

It is important to start with GDNF since it was one of the first to be tested on humans via delivery directly to the brain. GDNF is a protein that, in humans, is encoded by the GDNF gene. GDNF is a small protein that potently promotes the survival of many types of neurons. GDNF showed promising results in two Parkinson's disease clinical trial and in a number of animal trials; however, a study came out later that reported the results as a placebo effect and as a result the clinical studies performed by Amgen (AMGN) and Medtronic (MDT)were halted. Additionally, a safe and easy method of delivery became a significant roadblock for GDNF. Work on perfecting the delivery of GDNF to the targeted is ongoing and it is still believed to have clinical importance for the treatment of ALS and more recent studies suggest it could be used in reducing drug and alcohol addiction.

Below is a Q&A I had with Henri. My comments and questions below are in bold for clarity:

Me: GDNF was at one point very promising yet clinical studies were halted after roughly $300 Million was spent on research. From what I can gather a big problem that GDNF ran into was the ways in which it was delivered. Are there alternative ways in which to deliver MANF/CDNF that would make it less risky for humans?

Henri: GDNF was one of the first biologicals to be tested in humans via intracerebral delivery. There are many simple technical reasons that contributed to the failure of GDNF, and as you correctly pointed out, many of these point to the delivery being critical for efficacy. In the past ten years, intracerebral delivery technology for protein drugs has developed quite a bit - of course many lessons were learned from the GDNF trials. Also, during this time deep-brain stimulator has become a widely accepted aid for PD patients. The surgical operation for implantation of DBS electrodes is highly similar to implantation of infusion catheters. So, in a way, we are now well-positioned to start testing the efficacy of therapeutic proteins - instead of developing delivery technologies. Prof. Steven Gill has recently initiated a new Phase 2 study with GDNF in Bristol, using improved delivery methods.

Me: Were the GDNF tests performed with a naturally occurring version (or variant) or with a modified or non-natural variant?

Henri: One important contributor of GDNF's failure in the clinic was likely its very limited distribution in the brain. Natural forms of GDNF and many other related proteins such as Neurturin (Ceregene) bind strongly to extracellular matrix proteoglycans which limit its distribution after infusion. There are some strategies in development to alter these sites in GDNF/Neurturin to improve their distribution in the brain. Very importantly, the natural forms of CDNF and MANF do not bind to these heparin-type proteoglycans and distribute much more widely than GDNF/Neurturin when injected into the brain.

Me: I am curious to know what ties you have with MANF. I see that you recently challenged patents held by another company called Amarantus BioScience (AMBS) which were held up in court. Does Hermo Pharma hold patents on this? Could you shed some light on this for me?

Henri: Regarding the recent patent challenge, we strongly believe that the European Patent Office has made a significant mistake in granting the Amarantus's MANF patent a 90% sequence homology protection. The reason why we believe this is based on the following:

1.) Amarantus originally patented a non-natural form of the protein (probably a cloning artifact resulting in an amino acid change vs the naturally occurring form of MANF).

**My NOTE: Amarantus separately claims to have additional patents on the protein in SEC filings.

2.) A single amino acid change in a critical site in the MANF protein will entirely destroy its biological activity (several independent laboratories have confirmed this).

3) Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus.

Amarantus Therapeutics owns the MANF sequence patent. For clarity, human CDNF shares 59% amino acid identity with human MANF, so the MANF patents are by no means limiting CDNF development, or vice versa.

Me: Who owns the IP for CDNF?

Henri: Hermo Pharma owns all IP rights to CDNF. The composition of matter patent for CDNF has been granted in a large number of countries, including US and EPO region. In addition, we have filed a number of use patent applications for CDNF that are currently pending.

Me: Are there any large pharmaceutical companies involved in the research and testing of the novel family of neutrophic factors that MANF and CDNF are a part of?

Yes, there is interest in the big pharma. The field is burdened by the stigma caused by GDNF failures. Over the past 3-4 years, we have discussed with a large number of companies, small-mid-big pharma, and it has become very clear that if one of the small biotechs can provide proof of efficacy in human PD patients, this will bring the big players back in the game.

So what is the play?

At this time the only publicly traded company that is playing in this field is Amarantus (AMBS.OB). Amarantus owns sequence patents on MANF which were upheld in court after Hermo Pharma challenged them. As Henri mentioned, they challenged the patents because they believed that they covered too many possible variants of the protein and it therefore "causes "an undue burden" to anyone who would like to test these variants for activity". The only way I can interpret this is that anyone looking to test different variants of MANF will be forced to go through AMBS as it has patents "that cover all sequences with 90% homology to MANF".

After looking further at AMBS I came away with a list of some positives and negatives. Negatives always come first when assessing a micro-cap investment.

Negatives:

1.) Balance sheet is a risk, despite recent financing efforts. The company currently has roughly $600k in cash and a history of losses.

2.) There is still a stigma surrounding delivery methods of these neutrophic factors to the brain and other areas of the body; however, Henri seems to believe that there is already a good deal of progress on this front.

3.) Dilution risk - given that the company is very small and has had to issue shares in the past to raise capital, there is still further risk that they will need to raise capital via equity raises. Additional capital will need to be obtained through partnerships with larger pharma companies or through grants.

4.) The company is tiny, with only 3 full time employees and an outsourced clinical staff. While this is not uncommon (e.g., Hermo Pharma has 4 full time employees and an outsourced staff of around 20), it places additional emphasis on working with well seasoned advisors and directors that have had big pharma experience.

Positives:

1.) Probably the most important positive: Patent protection on MANF that was recently upheld in court.

2.) Almost equally as important, the company has a strong group of advisors with big pharma backgrounds and experience in bringing novel drug therapies to market. Below is a list of recently appointed advisor and what they had to say about the company's MANF program.

Dr. Joseph Rubinfeld, co-founder of Amgen, was recently appointed as an advisor to the company and had some very glowing things to say about MANF: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Dr. Robert Zimmerman from Bayer (BAYZF): "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
Clinton O. Allen from Bristol Myers Squibb (BMY): "I am very excited to join Amarantus at this critical time in its growth cycle," said Clinton O. Allen, newly appointed advisor to Amarantus. "The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order meticulously evaluate proposals and make recommendations for future growth."
3.) The company has received two separate grants from the Michael J. Fox Foundation in 2010 and 2011 as well as a grant from the Center of Excellence in Apoptosis Research.

If AMBS is able to continue showing positive results in toxicology studies and preclinical data it is possible that larger pharmaceutical companies will seek a partnership with them. Having patent protection will certainly help them in negotiations and having a recent patent challenge upheld in courts could prove to be quite positive for them.

RISKS:

As always, micro caps are subject to significant risks and uncertainties. The micro cap field is littered with a lot of pump and dump companies and traders looking for short term moves. Volatity in this space is very high. Please do your own due diligence.

Disclosure: I am long AMBS.OB.

Additional disclosure: After doing a good deal of research on this field I am long AMBS. Please understand the risks of micro cap companies. They are highly volatile and subject to significant risks.

[haseausdemhut]

Amarantus BioSciences Issues First Annual CEO Letter to Shareholders
Date : 05/07/2012 @ 5:59AM
Source : PR Newswire (US)
Stock : Amarantus Biosci (AMBS)


.........MILESTONES

In the last year the Company has achieved the following important milestones:

Entered the public markets and significantly expanded our shareholder base;
Confirmed efficacy of our MANF Program in Parkinson's disease;
Received grant funding to initiate our MANF Program in Traumatic Brain Injury.
The most critical milestones for us to achieve in the next 12 months are:

Raising sufficient capital to efficiently fund our therapeutic and diagnostic programs;
Advancing our various product development programs to key value inflexion milestones;
Finalizing the business development transactions executed over the past 12 months;
Recruiting seasoned product development expertise in the areas of biopharmaceutical and diagnostic product development;
Listing our common stock on a national stock exchange.


----------------------------------------------------------------

[haseausdemhut]

AMBS

Advisor to the Board of Directors
Dr. Owen Garrick
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation.



Advisory Board
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.


Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.


Dr. Mark Benedyk
Corporate Advisor
Dr. Benedyk, is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Among other things, in this role, he is a Strategic Advisory Board member to a clinical-stage neuropsychiatry specialty care company, is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University’s Graduate School of Business, and the University of Virginia Darden School of Business.



Clinton Allen
Corporate Advisor
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.


Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.

[haseausdemhut]

14.12.2012

Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test
Download PDF

SUNNYVALE, Calif., Dec. 14, 2012 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc. LymPro originated from the University of Leipzig in Germany and has received over $3 million in research grants from the National Institutes of Health (NIH).

LymPro was designed with the purpose of diagnosing Alzheimer's in its mild to moderate stage, a population of patients currently being tested in numerous clinical studies with amyloid-beta targeting strategies. LymPro works by identifying immune-based biomarkers in the blood of Alzheimer's patients, diagnosing Alzheimer's and allowing physicians to definitively differentiate Alzheimer's disease from other forms of dementia. This patient-specific identification has the potential to become an invaluable tool for Alzheimer's disease clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of Alzheimer's. LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study. If successful, LymPro can begin generating revenue as a laboratory developed test ("LDT") within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research.

"We believe LymPro has significant clinical and commercial potential as a diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong, President and CEO of Amarantus. "It is clear that the path forward for treating Alzheimer's disease is to identify and initiate therapeutic intervention as early as possible. If proven effective, LymPro could provide physicians with a lower-cost, minimally-invasive intervention and reduce the need for costly brain imaging scans. This license expands our diagnostic pipeline and complements our strategic focus on neurodegenerative diseases. While we are not currently developing MANF for Alzheimer's disease, we believe that the cost-effective definitive identification of earlier-stage patients will create a significant opportunity for Amarantus to evaluate the MANF Program as a disease-modifying treatment in this large, underserved therapeutic indication."

Under the terms of the agreement, Amarantus has agreed to issue two million shares of restricted common stock to MDx, pay a development milestone upon successful completion of the Phase 2 validation study, as well as pay a nine percent royalty on sales. In addition, Amarantus has agreed to retain MDx to perform the necessary validation study to gain Clinical Laboratory Improvement Amendments (CLIA) certification for LymPro. Together, Amarantus and MDx will expand their relationships with large pharmaceutical companies, and will also seek additional grant funding for the further development of LymPro. Amarantus has the right to assign or sub-license LymPro to a third party of its choosing at any time.

"Amarantus represents an excellent partner for Memory Dx because of its scientific focus on protein misfolding and aggregation, which we believe will continue to be critical in developing disease-modifying treatments for Alzheimer's," said William E. Gartner, President and CEO of Memory Dx, LLC. "This agreement with Amarantus is the final step in the transition of Memory Dx from a diagnostic product developer into a contract CLIA lab focused on driving revenues. We look forward to working with Amarantus to advance LymPro and get it into the hands of physicians so we can help address the significant socioeconomic problems caused by Alzheimer's disease."

About Alzheimer's Disease

It is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease and over 300,000 patients are diagnosed annually, with nearly one in eight older Americans affected by the disease. Alzheimer's is the sixth leading cause of death in the United States. The estimated cost of unpaid care in the United States is estimated at over $210 billion annually and the total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. It is estimated that these figures will double by 2050. Amarantus believes the market opportunity for an effective Alzheimer's disease diagnostic far exceeds $500 million annually.[1]

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

[1] http://www.alz.org/alzheimers_disease_facts_and_figures.asp

MEDIA CONTACTS

Amarantus Bioscience, Inc.
[phone]
[e-mail]

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
[e-mail]

[haseausdemhut]

"LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study. If successful, LymPro can begin generating revenue as a laboratory developed test ("LDT") within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research".

$500 million annually=2$ Price per share ONLY LYMPRO!

THERE IS NOT SO MUCH TO CALCULATE!

Amarantus believes the market opportunity for an effective Alzheimer's disease diagnostic far exceeds $500 million annually.

LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study.

Amarantus BioScience Licenses LymPro Alzheimer's Disease Diagnostic Blood Test

ih.advfn.com/p.php?pid=nmona&article=55465452

[haseausdemhut]

CHAIRMANSBLOG AMBS CEO:

MANF: Arresting cell death in Parkinson’s disease, Traumatic Brain Injury, Cardiac Ischemia and more

Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.

Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.

Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:

1.Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2.Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3.Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4.Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.

I thank you for taking the time to read this letter and looking forward to communicating with you in the future.

Gerald E. Commissiong

President & Chief Executive

http://www.thechairmansblog.com/gerald-commissiong/2012-12/m…

[haseausdemhut]

platform Drug, MANF!
Potential fixes/cures for all the following:

MANF for disorders About GeneDecksing

OMIM gene information: 601916 OMIM disorders: --

28 diseases for MANF:
rheumatoid arthritis parkinson's disease arthritis carcinoma
cleft lip squamous cell carcinoma of the head and neck cytomegalovirus infection brain injury
growth hormone deficiency neurodegenerative disease neuronitis dna topoisomerase i
squamous cell carcinoma glaucomae glaucoma renal cell carcinoma diabetes Alztimers
twinning periodontitis esophageal cancer ovarian cancer
pancreatic cancer pancreatitis prostate cancer esophagitis
retinitis immunodeficiency hepatitis prostatitis

Yup, I'd say we have a BLOCK BUSTER on our hands!

[haseausdemhut]

seekingalpha.com/article/1072461-pharma-continues-to-move-forward-with-alzheimer-s-therapies?source=yahoo


NEWS abaout AMBS in combination with APPLE by seekingalpha!!!


Since my previous article on Alzheimer's, we have seen some developments in the area of developing a successful treatment for Alzheimer's disease. For those unfamiliar, the unmet need in the area is large with some projecting a global market size for a highly effective treatment could be as much as $20 billion. That sizeable market has attracted the likes of big pharma, who are looking for ways to reinvent themselves and find new avenues of growth. Help for Alzheimer's patients has even come from the likes of Apple (AAPL), with its Alzheimer's iPhone app, that provide families with fresh approaches to improving one's quality of life. With an estimated 5 million patients in the U.S. and 26 million worldwide, a success therapy would have significant positive developments from a societal and economic point of view.
.....Amarantus BioScience (AMBS.OB) just announced that it licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx (MDx). LymPro was designed with the purpose of diagnosing Alzheimer's in its mild to moderate stage, a population of patients currently being tested in numerous clinical studies with amyloid-beta targeting strategies. LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study. If successful, LymPro can begin generating revenue as a laboratory developed test within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research.

Other recent news for the company includes news on data for its trials. The company in late November announced that it successfully completed experiments demonstrating that MANF, its proprietary anti-apoptosis therapeutic protein, has an excellent diffusion profile in the striatum of rat brains. The striatum is located in the brain, and is partially responsible for proper movement as part of the basal ganglia network. The striatum becomes severely compromised in Parkinson's disease due to neurite retraction from dopaminergic neurons located in the substantia nigra. The data generated in this study show that when compared to GDNF, a neurotrophic factor currently in a Phase 2 clinical trial for Parkinson's disease, MANF had a significantly higher volume of distribution when delivered to the striatum.

[haseausdemhut]

News:20.12.2012

http://www.finanznachrichten.de/nachrichten-2012-12/25522436…

[haseausdemhut]

21.12.2012

k8

http://content.stockpr.com/sec/0001144204-12-069007/00011442…


K8 ist sehr gut. es ist besser als sehr gut.

für haben Lympro ( ihr errinert euch 98% bzw 96% erfolgsquote! wie ich...)
Lympro trial I abgeschlossen -> trial II, in 12 bis 18 monaten im markt.
marktkapazität: 500 millionen $ jährtlich.

2 millionen shares jetzt, 1 millionen $ nach erfolgreichem abschluss.

wenn es erfolgreich abgeschlossen ist sind wir ohnehin marktreif! wir haben 500 millionen $ jährlich zu erwarten.
mit dieser prognose anders formuliert, wenn wir der marktreife nähern (nebenbei haben wir noch Nuropro (viel weiter entwickelt trial II->III) und (Manf vermutlich in den nächsten monaten bereits in trial phase))

also wenn wer mit Lympro der marktreife nähern sind auch die anderen beiden produkte weiterentwickelt, zudem haben wir jährlich 500 millionen einnahmen zu erwarten. die aktie bereits im august vermutlich 2$ bis 4$ kosten.
wenn es bei 1$ sein sollte wird amarantus nach vertragsverpflichtung entweder 1 million $ zahlen oder 1 million aktien geben, bei 2$ wird amarantus 500tausen aktien geben..

es ist ein großartiger deal.

die nachricht von gestern mittag über die veröffentlichung der resultate über MANF bei der onemedplace conference stattfindet ist ein sehr gutes zeichen, vor allem dass dr rubinfeld (muss ich es noch erwähnen der cofounder von amgen) die presentation mithällt und die wirtschaftlichen aspkete durchleuchtet ist grandios. es wird live übertragen, jeder kann mitverfolgen wenn der master der guru spricht.


jeder der in vergangenheit in amgen 2000$ investiert hat kann jetzt auf stolze 9,000,000$ (neun millionen dollar)blicken( von 0,02 auf 90$).

jeder der 10,000$ in amarantus investiert kann in unvorstellbar kurzer zeit 1,000,000$ im kontoauszug bewundern (0,03 auf 3$).

[haseausdemhut]

[haseausdemhut]

Jet Life Penny Stocks Top 5 Picks: RIMM, FB, MSFT, YHOO, AMBS
Research in Motion (10.60$ share, 5.50 billion marketcap)
Facebook (26.90$ share, 58.00 billion marketcap)
Microsoft (27.00$ share, 227.50 billion marketcap)
Yahoo (19.65$ share, 23.00 billion marketcap)
AMBS (1.50$ share, 336.00 million marketcap)

AMBS BETWEEN MULTI BILLION INTERNATIONAL CONCERN! AMBS IS GOING THE RIGHT PLACE! (1.50$ is from me, and its still looks so cheap! Know what you own! 0.076$ is just a joke, and dont gives the real value of the HOTSOCK OF THE YEAR 2013 back says Hase!)

Jet Life Penny Stocks Top 5 Picks for After Christmas: RIMM, FB, MSFT, YHOO, AMBS

Stamford, CT -- (SBWIRE) -- 12/24/2012 -- Jet Life Wishes Investors and Traders a very Merry Christmas! Please check out these hot stocks after Christmas

http://www.sbwire.com/press-releases/sbwire-191036.htm

[haseausdemhut]

Amarantus BioScience Acquires Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical Products

SUNNYVALE, Calif., Dec. 26, 2012 /PRNewswire via COMTEX/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced the Company has purchased all of the intellectual property (IP) assets from Power3 Medical Products. Power3 was in bankruptcy, giving Amarantus the ability to acquire all of Power3's the IP for the diagnosis of multiple neurodegenerative diseases and oncology for $40,000 USD.
With the acquisition of these assets, Amarantus added following issued patents to its portfolio:

-- 12/802,630 - Diagnosis of Parkinson's Disease

-- 13/118,175 - Assays for diagnosis and therapeutics...ALS and Parkinson's Disease

-- 12/069,807 - 47 Protein Biomarkers for Neurodegenerative Diseases

-- 12/804,868 - Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders

-- 13/153,669 - Diagnosis of Alzheimer's Disease

As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia (CML). The Company also acquired all of the data generated by Power3 while creating its IP portfolio. All of the disease states covered by the intellectual property acquired from Power3 are related to Programmed Cell Death (Apoptosis).

"The patents, patent applications and supporting data sets acquired as part of this as transaction are a tremendous addition to our intellectual property estate, and fit well into the overall diagnostics strategy Amarantus is pursuing to support our therapeutics programs," said Gerald E. Commissiong, President and CEO of Amarantus. "We are now poised to advance our diagnostic pipeline for Parkinson's disease and Alzheimer's disease towards commercialization."

In addition, Amarantus has retained the services of Dr. Essam Sheta, former CLIA Laboratory Director at Power3, to assist the Company in preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro� Parkinson's Disease Blood Test.

Earlier this year, Amarantus entered into an exclusive worldwide license agreement with Power3 for the Company's NuroPro Blood Test as it relates to Parkinson's disease diagnosis. With the acquisition of Power3's IP, Amarantus now owns the patents underlying the license and has no further financial obligations to Power3.

About Amarantus BioScience, Inc.

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS

Amarantus Bioscience, Inc.(408) [e-mail]

Investor/Media Contact:IR Sense, LLCRemy [e-mail]

SOURCE Amarantus BioScience, Inc.

[haseausdemhut]

27.12.2012

[haseausdemhut]

Amarantus BioScience an Biotech Showcase 2013 Präsentieren

SUNNYVALE, Kalifornien , Dezember 27, 2012 / PRNewswire / - Amarantus BioScience, Inc. (OTCQB: AMBS), ein Biotechnologie-Unternehmen, die Entwicklung von Therapien und Diagnostika für Krankheiten, die mit Neurodegeneration und Apoptose um seine patentierte Anti-Apoptose-therapeutisches Protein MANF zentriert verbunden sind, gab heute bekannt, dass President & CEO Gerald Commissiong eine Unternehmenspräsentation am Biotech Showcase 2013 machen Mittwoch 9. Januar 2013 am 09.00 PST im Parc 55 Wyndham Hotel in San Francisco, CA. Die Unternehmenspräsentation am Biotech Showcase 2013 geleistet wird der Tag nach der Präsentation werden Parkinson neurorestoration tierexperimentellen Daten von CSO Dr. John Commissiong und gleichzeitigen wissenschaftlichen Überblick über die breitere MANF Chance Dr. Joseph Rubinfeld , ein Berater Amarantus. Die Gesellschaft wird sich die Biotech Showcase 2013 Link zum Webcast auf seiner Website unter www.amarantus.com mehrere Tage vor der Veranstaltung.

"Die Vorträge geplant die Woche der Healthcare-Industrie größte jährliche Versammlung der wichtigsten Entscheidungsträger in San Francisco eine ideale Plattform, um Amarantus der breiteren Investment Community und biopharmazeutische Führungskräfte einzuführen bieten ", sagte Gerald E. Commissiong , President & CEO.

Über Biotech Showcase ™ 2013

Biotech Showcase ™ ist eine Investoren-und Partnering-Konferenz zur Aufgabe, private und Small-und Mid-Cap-Biotech-Unternehmen die Gelegenheit, sich zu präsentieren und sich mit Investoren und biopharmazeutische Führungskräfte im Verlauf eines der größten jährlichen Gesundheits-Konferenzen, die Investoren und biopharmazeutische zieht Führungskräfte aus der ganzen Welt .

Der 2012 Veranstaltung zeigte einen deutlichen Anstieg bei der Zahl der präsentierenden Unternehmen, sowie ein deutliches Wachstum in der Anzahl der Teilnehmer und One-to-One-Meetings. Jetzt in seinem fünften Jahr wird Biotech Showcase 2013 erwartet Präsentationen von knapp 250 öffentliche und private Unternehmen bieten und locken mehr als 1.500 Teilnehmern. Die Veranstaltung findet auch eine vollständige Programm der aktuellen Plenarsitzungen und Workshops. www.biotechshowcase.com

[haseausdemhut]

Amarantus BioSciences Issues CEO Letter to Shareholders


(OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below.

Dear Shareholders,

I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.

As was recently announced, we were able to strengthen the corporation's balance sheet by raising cash and reducing liabilities. These financing transactions were vital for the Company to pay certain vendors who are critical to on-going operations, as well as raise sufficient working capital to pursue our corporate strategy, as detailed below. Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development.

With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investors and potential partners to the Company and its technologies.

Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF is the Company's primary asset. Management believes that MANF has broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (Programmed Cell Death) in response to injury or disease. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF in the right areas and at the right time. In so doing, we are not fundamentally changing what the body does; instead, we are helping the body do what it does better to overcome injury or disease. This approach appears to be in the mainstream of thought leadership both in academia and industry, and Amarantus is positioning itself to be a leader in the field.

Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF. The Company's portfolio covering the MANF protein, gene and use as a cell therapy adjuvant is extensive and robust. We are initially focusing on the development of MANF-based protein therapeutics. In order to improve our portfolio, we are continually enhancing our IP position through the filing of additional patents, in-licensing, and acquisition of related and complementary intellectual property. These endeavours have positioned the Company for long-term success by cornering the MANF-related market and forcing future potential partners or acquirers to deal solely with Amarantus in order to get access to MANF. We will continue to prosecute this strategy to the best of our ability.

The Company has implemented a strategy centered on developing MANF in areas where partnerships with not-for-profit organizations and granting agencies are readily available. These partnerships have garnered support for Amarantus from thought-leaders and have offset some of the financial burden of running proof-of-concept studies. The Company has already taken steps to improve our prospects in future partnering discussions from a corporate structure standpoint, and we will continue to improve MANF's prospects by focusing on further differentiating MANF from its competition, especially in Parkinson's disease. To further this objective, we have added certain key advisors to assist management in preparing a winning strategy to obtain the most value from our MANF program. With these new additions, we have gained access to significant intellectual capital, as well as invaluable insight into the realm of preparing both our asset and our corporation for successful partnerships.

MANF's current lead indication is Parkinson's disease, an area where we have produced very promising results. We have also achieved positive data in Traumatic Brain Injury (TBI) through our collaboration with Banyan Biomarkers. Our #C4CT program has attracted significant attention among NFL players and other professional athletes who have suffered from brain injuries, and we intend to leverage those relationships to raise awareness of MANF's potential role in TBI. In addition to Parkinson's disease and TBI, MANF has shown to be effective across a broad range of indications. The recent publication of myocardial infarction data validating a MANF-based approach has added significant value to our patent portfolio. Myocardial Infarction is a $5B market where there are currently no approved drugs to address the ischemia and reperfusion related injuries associated with heart attacks.

Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe.

NuroPro & LymPro

Amarantus licensed the NuroPro Parkinson's disease Blood Test in January 2012. NuroPro identifies various markers in the blood of patients suffering from Parkinson's disease that do not appear in the blood of non-diseased people. The importance of this asset cannot be overstated. The early diagnosis of Parkinson's disease is the gating step to evaluating new treatment options on patients that have the highest likelihood of responding. The development of NuroPro will further enable our MANF program by giving the Company critical insight into the overall process of patient selection, and may allow us to fine-tune our development protocols towards the identification of a sub-population of Parkinson's patients most likely to respond to MANF. We are currently recruiting the expertise required to advance the blood test, as NuroPro may provide Amarantus a path to revenue generation sooner than with MANF alone.

The Company previously announced that we have acquired an exclusive option to license the LymPro Alzheimer's disease Blood Test from Memory Dx (formerly Provista Life Sciences). The Company is continuing to negotiate that license with the intent of pairing LymPro with NuroPro and presenting a compelling package of diagnostic assets.

We will continue to update shareholders on advancement of both NuroPro and LymPro. In addition, management constantly evaluates the competitive landscape for complementary product candidates that could improve the overall prospects of the Company in the most cost-effective manner possible.

In Closing

We are at a very exciting time here at Amarantus. We have secured the resources and advisors to advance our current assets and expand our business development efforts. We will implement this strategy by honing in on our core program, MANF, and finding innovative solutions to further enable MANF's development and secure Amarantus' ownership of the MANF space. We are encouraged by our data to date, and continue to believe the asset has blockbuster potential.

Your Board of Directors and management team remain dedicated to improving the lives of patients suffering from a variety of illnesses and diseases. We are motivated by the prospects of the company, and our primary focus remains: progressing our assets to help patients and increase shareholder value. I would like to personally thank each of you, and will work to ensure your trust is maintained as Amarantus grows.

Thank you,

Gerald E. Commissiong
President & Chief Executive Officer

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

Amarantus BioSciences, Inc.
[phone]
[e-mail]

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
[e-mail]

SOURCE Amarantus BioSciences, Inc.


Copyright 2012 PR Newswire

[haseausdemhut]

realtimechart

[haseausdemhut]

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

How bout that 8-K? So, in summary, what do we have so far? I won't go into all that has been rehashed....here's a quick primer:

We have a company that is transparent, the CEO "seems" to give a #$%$ about the people that believe in his companies efforts, a symbol change to protect shareholders from the Berlin stock exchange and shorting efforts, a victorious lawsuit upholding their patents (again, if they didn't have anything, why would someone try and take it?), numerous members of the board that are industry experts that specialize in bringing the big guys to the table, a postponed reveal of their test results until a time that it will really matter ie, the Jan 8th conference, and the grand daddy of them all, a measure to protect the shareholders from a hostile bid takeover (that's what it was wasn't it?).....right before they present the said results.

Why would they feel the need to do this if their results would not warrant it? They have something and they know it. Their legal counsel has obviously advised them wisely if the company believes that what they have, others will want. They seem to be positioning themselves in the direction of a huge success.

All this because, they're not sure or the results are mediocre at best? We already know what they have (MANF) works and they must know/believe that it will work in humans. Do you wait until the human trial are complete? What more would you need to see in terms of information to make you believe that they are on to something big? I have yet to see anything (well other than the occasional stupid #$%$ post from a basher) that makes me think that this won't be , as Dr Rubinfeld has stated......"a blockbuster drug".

He is co-presenting it at the conference, is he not? Would he risk his reputation on something he knew wasn't a game changer? Well, of course unless he was really hurting for cash, which I doubt. Lets make this board about the FACTS as we see/find them and just ignore those that have obvious agendas. No need to even comment on them and if ya want to shut them up, just don't comment. If the FACTS change, then lets discuss them, but please, refrain from just throwing out figures/share prices on events that have not happened. People who will be coming to this board, looking for information on the stock will tend to be turned away when they read the usual penny stock jargon, insults and shenanigans. Lets be smart here people and work together to help each other achieve what could be...financial windfalls. Stay informed, and share what you find to be relevant. Peace and good luck

[haseausdemhut]

NOKOMIS, Fla.—Amarantus Biosciences and Rainbow Coral Corp. (RBCC) subsidiary Rainbow BioSciences are moving toward the finalization of the terms for a joint-venture agreement that will see the organizations working to progress NuroPro, Amarantus’ Parkinson’s diagnostic platform, towards commercialization.

The deal, for which RBCC has prepared a joint-venture term sheet, is intended to aid in the completion of the NuroPro program. The NuroPro test identifies differentiated levels of proteins and peptides in the blood of patients who have Parkinson’s versus those who do not. NuroPro has completed a Phase I human clinical trial, and Amarantus and RBCC expect to initiate Phase II clinical studies next year. It is expected that once Phase II is complete, NuroPro will begin generating revenue through sales under the Clinical Laboratory Improvement Amendment certification.

“Amarantus’ focus on Parkinson’s disease has allowed it to gain considerable traction with partners who understand the potential value of the technologies we have in-house,” Gerald E. Commissiong, president and CEO of Amarantus, said in a press release. “This transaction will allow Amarantus to gain upside from the licensing of the NuroPro asset, while defraying the costs of the project in order to focus our internal resources on the MANF program for Parkinson’s disease and traumatic brain injury. As NuroPro advances towards commercialization, we expect it could become a key differentiating component of our clinical development program of MANF for Parkinson’s disease.”

The companies first made contact in February, says Commissiong, noting that they engaged with RBCC soon after completing the license for NuroPro, which he says was “a complete positioning of the company in the Parkinson’s space with a diagnostic and a drug vertically.” The agreement and commercialization of NuroPro will allow Amarantus to “really become a market leader positioning ourselves in Parkinson’s.” A 2011 report by Visiongain analysts forecasts that the Parkinson’s disease market could grow to $3.75 billion by 2015.

“This is a cutting-edge approach to diagnosing a debilitating disease that has afflicted millions of people worldwide,” RBCC CEO Patrick Brown said in a statement. “The marketplace is crying out for new breakthroughs in the diagnosis of neurological diseases, and we believe NuroPro has the potential to diagnose Parkinson’s disease early, allowing physicians to initiate treatment regimens earlier, as well as conduct research of clinical-stage disease-modifying treatments on earlier-stage patients.”

In addition to NuroPro, Amarantus is also developing its MANF program. MANF is “an endogenous, highly-conserved, ubiquitously expressed and highly potent secreted human growth factor up-regulated in the adaptive pathway of the Unfolded Protein Response resulting in the prevention of apoptosis,” Amarantus notes on its website, and “by mediating this critical biological process, MANF is highly indicated for the treatment of several poorly served medical conditions, including Parkinson’s disease and ischemic heart disease.” It is thought that MANF will be able to protect dopamine-producing neurons from apoptosis and revitalize dying cells to stop the progression of Parkinson’s disease and restore normal function.

The University of Massachusetts’ Pioneer Valley Life Sciences Institute’s Center of Excellence in Apoptosis Research has awarded Amarantus a Translational Research Grant award to identify additional indications in which MANF could have therapeutic potential. Commissiong says progress for the program is slow but steady, and that the data so far has been “over the top as far as what we’ve seen in the potential of the technology.”

“What we have appears to be very broad in terms of applicability, and it looks as though we have a number of application areas that could be rather quick to market. And that’s really one of the keys for us,” he explains. “So what we’ve done, basically, is we said okay, we’re going to focus on MANF, we’re going to keep Parkinson’s as our lead vertical for a number of reasons, primarily medical needs and relationships in product positioning, but we’re really going to start to evaluate the potential applications, especially with new data that’s come out related to MANF having an effect in vivo in a model of myocardial infarction and a grant that we just received from the Center of Excellence in Apoptosis Research in Massachusetts to identify new indications for MANF.”

“It’s very clear MANF has applications in a number of disease areas,” says Commissiong. “It’s very clear that we’re only scratching the tip of the iceberg as far as what it could do.”
Code: E111213

[haseausdemhut]

Amarantus AMBS:
Nuropro: trial ll-lll-»market 12 mon
Lympro: trial l-ll-»market 12-18 mon mit ODAstatus.
MANF: preklinik vermutlich in kuerze trial l. MANF besser als GDNF in trial ll.
market mit ODA status in bis 18 mon.

Lympro market: 500mil$ jährlich
Nuropro market 500 mil$ jährlich
MANF market 8 billion $ jährlich

SIND 2 BILLION $ IM JAHR KONSERVATIV GENUG?!
=
KGV 10 = 20 billion marketcap.

ca 224 million aktien
1 billion (us) a/s
dilution rechnerisch max weitere 270 mil. Aquisition inbegriffen.

bei 20 billion marketcap und 500million aktien = 40$.
MINUS 90% ÜBERTREIBUNG=4$.


board of director/advisors:
cofounder von amgen (aktie von 0,02 auf 90$)
president national health foundation
bayer biotech director
Novartis director
Pfizer director
Myer scuibb senior director
Took Superbowl champion

K8 ist als aktionaersrundumschutz zu verstehen.
feindliche übernahme nicht mehr möglich. abjetut muss schon einen vernünftigen angebot machen.

[haseausdemhut]

2 AMBS BOARD OF DIRECTOR ÜBER AMBS:


Clinton O. Allen from Bristol Myers Squibb (BMY) on AMBS: "I am very excited to join Amarantus at this critical time in its growth cycle," said Clinton O. Allen, newly appointed advisor to Amarantus. "The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order meticulously evaluate proposals and make recommendations for future growth."

Dr. Robert Zimmerman from Bayer (BAYZF) on AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic

[haseausdemhut]

!

Dieser Beitrag wurde von CloudMOD moderiert. Grund: Auszug aus Individualkommunikation

[haseausdemhut]

die ersten supports von den ganz großen;-)

$!

[haseausdemhut]

BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Print
Alert


Amarantus Bioscience, Inc. Common stock (OTCBB:AMBS

Intraday Stock Chart

Heute : Thursday 3 January 2013
Click Here for more Amarantus Bioscience, Inc. Common stock Charts.

Approximately 379 Million Shares Shorted Since June 2011
Short Squeeze Continues As Stock Above $0.0484 SqueezeTrigger Price




BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB:AMBS) after releasing the latest short sale data through January 2, 2013. The total aggregate number of shares shorted since June 2011 is approximately 379 million shares. Approximately 28.88% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.0484. A short squeeze is well underway as stock is above its SqueezeTrigger Price.

[haseausdemhut]

wer noch eine K8 von weinachten (aktionärsshutzmaßnahmen) fuer dummys mit erklaerung haben will:

in blau ist die erklaerung.


https://docs.google.com/document/pub?id=1xHgjgeDtLZCjnXzpBNn…

[haseausdemhut]

3/Jan/13 Update:
Amarantus Bioscience DD Compilation

Stock Board Assets

Fellow AMBS longs,

Over the past 8 trading hours we’ve seen a very healthy pull back forming support in the .14s. All longs still in the hunt are sitting on nice profits, and now we have shaken out a lot of flippers and weak hands in exchange for new investors. A retracement of this nature was inevitable and is the other side of this AMBS beast. I picked up a couple more shares in the low .15s and high .14s today, and have been watching the intraday closely all day. I am not worried at all about our long position and am still equally as optimistic as I have been this whole ride. Our data presentation after market close on January 8th will provide a MAJOR catalyst that is fundamentally natural and organic as opposed to bogus reports like the buyins.net squeeze trigger articles. Not only are we expecting data that shows ~30% better results than a drug, GDNF, valued at $250 million preclinical, but Dr. Rubinfield will be presenting immediately after on the commercialization potential of MANF. This conference is not one of those assemblies where a bunch of science dorks come together to show off their projects, its an investors conference. We have one of the most reputable scientists of the past century ready to talk about some HUGE, multi billion dollar markets MANF is preparing to run for. Not only will this potentially bring in much needed funding for AMBS, it will bring in a lot of deep pocket investors who will be joining us longs in the ride of a lifetime. Don’t lose sleep over the day-to-day movement of this stock. All your focus should be on the true value of MANF and AMBS, and the data coming out as positive as we expect. This is all just white noise in the grand scheme of things.

$2 coming sooner rather than later

DEN LINK ÖFFNEN UND UNBEDINGT LESEN!

https://docs.google.com/document/d/1V10erwVdBvy6Um35Ay8XV0wV…

[haseausdemhut]

6.januar.2013



NEBEN DER 50 200 TAGE CROSS (GOLDENCROSS) VOR PAAR TAGEN (KAUFSIGNAL FÜR CHARTISTEN)

KOMMT DER NÄCHSTE CROSS:

100 UND 200 TAGE KREUZEN SICH DEMNÄCHST!

http://www.investopedia.com/terms/g/goldencross.asp#axzz2H9Y…

0,15-0,17..chattechnisch von hier aus gesehen werden wir vermutlich einen 10x bagger erleben.

goldencross 50 200 tage vor paar tagen:




der nächste cross 100 200 tage in kürze:

[diamanten53]

Antwort auf Beitrag Nr.: 43.986.557 von haseausdemhut am 06.01.13 04:52:21

lieber Hase, bitte erkläre doch mal, was meinst du mit einem 10x Bagger...ich weiß es nicht und ich glaube, ich bin nicht der einzige, DANKE!

[Larry_1]

Guten morgen

jetzt wird es aber richtig kompliziert



die Idee von Hase, die Facebook Gruppe zu generieren, finde ich ok.
Nachteil ist natürlich, das der Rest der Leute einfach abgehängt wird

franzisca hat gestern abend einen Faktenthread eröffnet, der gleich mal vom Hase bis in die frühen Morgenstunden "gefüllt" wurde.
(ich frage mich ernsthaft, wie das unser Hase auf Dauer durchhalten will??)

Problem ist doch wohl, das jeder von uns wenig Zeit hat, und deshalb nicht mehrere Foren bedienen kann.
Allein, die Infos von letzter Nacht, die Hase in den Faktenthreat reingestellt hat http://www.wallstreet-online.de/diskussion/1178659-51-60/ama…
überfordern viele Leser, wenn diese auf Deutsch wären. In englisch, na ja was soll ich dazu sagen, lesen und verstehen vielleicht 10% der User.

Also, meiner Meinung nach, sollten wir bei WO nur einen Thread führen (es ist total nervig ständig hin und her zu schalten, lesen und schreiben zu müssen).
Eine saubere Struktur werden wir bei so vielen Leuten sowieso nie erreichen


So das war das Wort zum Sonntag
Ciao

[ghaq]

*ROTFALPUPZ*

[diamanten53]

Antwort auf Beitrag Nr.: 43.986.897 von ghaq am 06.01.13 12:29:59

was meinst Du

[Larry_1]

Zitat von diamanten53: was meinst Du

hat noch Restalkohol!!

[Popeye82]

Zitat von haseausdemhut: wie die börse funktioniert....

Ist nicht schlecht. Vom Prinzip her hat ers denke ich voll getroffen.

Gruß
P.

[haseausdemhut]

Antwort auf Beitrag Nr.: 43.986.805 von diamanten53 am 06.01.13 11:37:44

diamant grüße Dich, 10xbagger bedeutet das eine aktie 1000% steigt.

Popeye finde ich auch, er hat es auf den punkt gebracht.

[CloudMOD [Mod]]

Guten Abend liebe User,

da sich hier offenbar eine neue Diskussion bildet und der eigentliche Sinn abhanden kommt, schliessen wir diesen Thread und ihr diskutiert bitte im Thread: **Amarantus Biosciences** hebt ab

Vielen Dank.

Freundliche Grüße CloudMOD